Recent advances in pharmacotherapy for dyspnea in COPD

Current Opinion in Pharmacology

Volumn 11, Issue 3, 2011, Pages 204-210

  Raghavan, Natya ^a   Webb, Katherine ^a   Amornputtisathaporn, Naparat ^a   O'Donnell, Denis E ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARFORMOTEROL; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FUROSEMIDE; HELIOX; HELIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDACATEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYGEN; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PRAVASTATIN; ROFLUMILAST; SALMETEROL; SEROTONIN UPTAKE INHIBITOR; TIOTROPIUM BROMIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; HUMAN; LETHARGY; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BRONCHODILATOR AGENTS; DYSPNEA; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79960198507     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.03.002     Document Type: Review

References (47)

1. K.F. Rabe, S. Hurd, A. Anzueto, P.L. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, and J. Zielinski Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 2007 532 555 (Pubitemid 47403272)
2. K. Nishimura, T. Izumi, M. Tsukino, and T. Oga Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD Chest 121 2002 1434 1440 (Pubitemid 34499652)
3. American Thoracic Society Consensus Statement Dyspnea. Mechanisms, assessment, and management Am J Respir Crit Care Med 159 1999 321 340
4. D.E. O'Donnell, J. Ora, K.A. Webb, P. Laveneziana, and D. Jensen Mechanisms of activity-related dyspnea in pulmonary diseases Respir Physiol Neurobiol 167 2009 116 132
5. D.E. Donnell, N. Voduc, M. Fitzpatrick, and K.A. Webb Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Eur Respir J 24 2004 86 94 (Pubitemid 39029073)
6. D.E. Donnell, T. Fluge, F. Gerken, A. Hamilton, K.A. Webb, B. Aguilaniu, B. Make, and H. Magnussen Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Eur Respir J 23 2004 832 840 (Pubitemid 38807355)
7. F. Maltais, A. Hamilton, D. Marciniuk, P. Hernandez, F.C. Sciurba, K. Richter, S. Kesten, and D.E. O'Donnell Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD Chest 128 2005 1168 1178 (Pubitemid 41324392)
8. T.J. Witek, and D.A. Mahler Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 21 2003 267 272 (Pubitemid 36204541)
9. E.R. Sutherland, S. Brazinsky, G. Feldman, J. McGinty, L. Tomlinson, and K. Denis-Mize Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI Curr Med Res Opin 25 2009 653 661
10. N.A. Hanania, J.F. Donohue, H. Nelson, K. Sciarappa, E. Goodwin, R.A. Baumgartner, and J.P. Hanrahan The safety and efficacy of arformoterol and formoterol in COPD COPD 7 2010 17 31
11. S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D.E. O'Donnell, A. McIvor, and S. Sharma Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease Ann Int Med 46 2007 545 555 (Pubitemid 351650535)
12. D.P. Tashkin, N.A. Hanania, J. McGinty, K. Denis-Mize, and I. Chaudry Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease Adv Ther 26 2009 1024 1034
13. D.P. Tashkin, J.F. Donohue, D.A. Mahler, H. Huang, E. Goodwin, K. Schaefer, J.P. Hanrahan, and W.T. Andrews Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD Respir Med 103 2009 516 524
14. C. Terzano, A. Petroianni, V. Conti, D. Ceccarelli, E. Graziani, A. Sanduzzi, and S. Serena D'Avelli Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD Respir Med 102 2008 1701 1707
15. J.F. Donohue, C. Fogarty, J. Lotvall, D.A. Mahler, H. Worth, A. Yorgancioglu, A. Iqbal, J. Swales, R. Owen, M. Higgins, and B. Kramer Once-daily bronchodilators for chronic obstructive pulmonary disease indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
16. A. Anzueto, G.T. Ferguson, G. Feldman, K. Chinsky, A. Seibert, A. Emmett, K. Knobil, D. O'Dell, C. Kalberg, and G. Crater Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes COPD 6 2009 320 329
17. T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, and R. Kessler Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 741 750
18. L.M. Fabbri, P.M.A. Calverley, J.L. Izquierdo-Alonso, D.S. Bundschuh, M. Brose, F.J. Martinez, and K.F. Rabe Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials Lancet 374 2009 695 703
19. P.M.A. Calverley, K.F. Rabe, U.M. Goehring, S. Kristiansen, L.M. Fabbri, and F.J. Martinez Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials Lancet 374 2009 685 694
20. D.A. Mahler, J.A. Murray, L.A. Waterman, J. Ward, W.J. Kraemer, X. Zhang, and J.C. Baird Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD Eur Respir J 33 2009 771 777
21. T.V. Santiago, C. Remolina, V. Scoles, and N.H. Edelman Endorphins and the control of breathing - ability of naloxone to restore flow-resistive load compensation in chronic obstructive pulmonary disease N Engl J Med 304 1981 1190 1195 (Pubitemid 11102797)
22. A.P. Abernethy, D.C. Currow, P. Frith, B.S. Fazekas, A. McHugh, and C. Bui Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea Br Med J 327 2003 523 528
23. D.C. Currow, B. Kenny, C. Mcdonald, K. Clark, and A.P. Abernethy Multisite open label dose ranging study to determine the minimum effective dose of sustained release morphine (SRM) for reducing refractory breathlessness 11th Congress of the European Association of Palliative Care Abstracts Eur J Palliat Care Suppl 2009 39
24. A.L. Jennings, A.N. Davies, J.P.T. Higgins, J. Anzures-Cabrera, and K.E. Broadley Opioids for the palliation of breathlessness in terminal illness Cochrane Database Syst Rev 4 2001 CD002066
25. M. Krajnik, Z. Podolec, M. Siekierka, M. Sykutera, E. Pufal, P. Sobanski, R. Makarewicz, C. Neef, N. Punt, and Z. Zylicz Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters J Pain Symptom Manage 38 2009 747 757
26. T. Sudo, F. Hayashi, and T. Nishino Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats Am J Respir Crit Care Med 162 2000 971 975
27. 2 ventilatory responsiveness in humans Pulm Pharmacol Ther 15 2002 363 368
28. S.H. Moosavi, A.P. Binks, R.W. Lansing, G.P. Topulos, R.B. Banzett, and R.M. Schwartzstein Effect of inhaled furosemide on air hunger induced in healthy humans Respir Physiol Neurobiol 156 2007 1 8 (Pubitemid 46228091)
29. K.C. Ong, A.C. Kor, W.F. Chong, A. Earnest, and Y.T. Wang Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease Am J Respir Crit Care Med 169 2004 1028 1033 (Pubitemid 38543642)
30. D. Jensen, K. Amjadi, V. Harris-McAllister, K.A. Webb, and D.E. O'Donnell Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD Thorax 63 2008 606 613 (Pubitemid 351969253)
31. A.J. Crockett, J.M. Cranston, J.R. Moss, and J.H. Alpers Domiciliary oxygen for chronic obstructive pulmonary disease Cochrane Database Syst Rev 4 2005 CD001744
32. M.M. Peters, K.A. Webb, and D.E. O'Donnell Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD Thorax 61 2006 559 567 (Pubitemid 44035134)
33. R.P. Moore, D.J. Berlowitz, L. Denehy, J.J. Pretto, D.J. Brazzale, K. Sharpe, B. Jackson, and C.F. McDonald A randomised trial of domiciliary, ambulatory oxygen in patients with COPD and dyspnoea but without resting hypoxaemia Thorax 66 2011 32 37
34. A.P. Abernethy, C.F. McDonald, P.A. Frith, K. Clark, J.E. Herndon II, J. Marcello, I.H. Young, J. Bull, A. Wilcock, and S. Booth Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial Lancet 376 2010 784 793
35. E.A. Laude, N.C. Duffy, C. Baveystock, B. Dougill, M.J. Campbell, R. Lawson, P.W. Jones, and P.M. Calverley The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease Am J Respir Crit Care Med 173 2006 865 870
36. N.D. Eves, S.R. Petersen, M.J. Haykowsky, E.Y. Wong, and R.L. Jones Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease Am J Respir Crit Care Med 174 2006 763 771 (Pubitemid 44511657)
37. D.D. Marciniuk, S.J. Butcher, J.K. Reid, G.F. MacDonald, N.D. Eves, R. Clemens, and R.L. Jones The effects of helium-hyperoxia on 6-min walking distance in COPD Chest 131 2007 1659 1665 (Pubitemid 46981617)
38. G.R. Chiappa, F. Queiroga, E. Meda, L.F. Ferreira, F. Diefenthaeler, M. Nunes, M.A. Vaz, M.C.L. Machado, L.E. Nery, and J.A. Neder Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 179 2009 1004 1010
39. N.D. Eves, L.C. Sandmeyer, E.Y. Wong, L.W. Jones, G.F. MacDonald, G.T. Ford, S.R. Petersen, M.D. Bibeau, and R.L. Jones Helium-hyperoxia: a novel intervention to improve the benefits of pulmonary rehabilitation for patients with COPD Chest 135 2009 609 618
40. D. Scorsone, S. Bartolini, R. Saporiti, F. Braido, M. Baroffio, R. Pellegrino, V. Brusasco, and E. Crimi Does a low-density gas mixture or oxygen supplementation improve exercise training in COPD? Chest 138 2010 1133 1139
41. N.P. Singh, J.A. Despars, D.W. Stansbury, K. Avalos, and R.W. Light Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety Chest 103 1993 800 804 (Pubitemid 23086178)
42. G.C. Man, K. Hsu, and B.J. Sproule Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease Chest 90 1986 832 836 (Pubitemid 17196171)
43. Y. Lacasse, L. Beaudoin, L. Rousseau, and F. Maltais Randomized trial of paroxetine in end-stage COPD Monaldi Arch Chest Dis 61 2004 140 147 (Pubitemid 40124039)
44. K.L. Rice, R.S. Kronenberg, L.L. Hedemark, and D.E. Niewoehner Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction Br J Dis Chest 81 1987 287 292 (Pubitemid 17091813)
45. A.A. Woodcock, E.R. Gross, and D.M. Geddes Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers Br Med J (Clin Res Ed) 283 1981 343 346 (Pubitemid 12250669)
46. T.M. Lee, M.S. Lin, and N.C. Chang Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin Am J Cardiol 101 2008 530 535
47. J.I. Keddissi, W.G. Younis, E.A. Chbeir, N.N. Daher, T.A. Dernaika, and G.T. Kinasewitz The use of statins and lung function in current and former smokers Chest 132 2007 1764 1771